Jakavi Tablet (Ruxolitinib) | Used for Blood Cancer and Bone Marrow Disorders
Jakavi Tablet (Ruxolitinib) is a targeted JAK inhibitor used in the treatment of myelofibrosis and other myeloproliferative disorders such as polycythemia vera. It works by blocking abnormal signaling pathways in blood and bone marrow cells, helping reduce spleen enlargement, control blood cell production, and improve disease-related symptoms
Product Overview
Jakavi Tablet is an advanced, targeted antineoplastic medication developed for the management of specific myeloproliferative neoplasms and immunologic disorders. Containing the active therapeutic compound Ruxolitinib, this small-molecule inhibitor directly targets the underlying cellular pathways responsible for abnormal blood cell production and systemic inflammation. Jakavi is primarily utilized to treat patients with myelofibrosis, polycythemia vera who are resistant or intolerant to hydroxyurea, and individuals suffering from acute or chronic graft-versus-host disease (GvHD). By downregulating hyperactive cellular signaling, the medication helps reduce debilitating systemic symptoms, manages spleen enlargement, and addresses underlying disease pathology.
Product Composition
- Active Pharmaceutical Ingredient: Ruxolitinib Phosphate (formulated in distinct tablet strengths including 5mg, 10mg, 15mg, and 20mg of pure ruxolitinib)
- Dosage Form: Round or oval, immediate-release solid oral tablets designed for precise, individualized dosing protocols
- Core Excipients: Formulated with standard pharmaceutical binders, including lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, povidone, and magnesium stearate
Product Specification
| Product Parameter | Details |
| Brand Name | Jakavi Tablet |
| Active Ingredient | Ruxolitinib Phosphate |
| Therapeutic Class | Antineoplastic Agents / JAK1 and JAK2 Kinase Inhibitors |
| Available Strengths | 5mg, 10mg, 15mg, 20mg |
| Primary Indications | Myelofibrosis, Polycythemia Vera, and Steroid-Refractory Graft-versus-Host Disease (GvHD) |
Mechanism of Action
- Selective JAK Kinase Inhibition: Ruxolitinib functions as a highly selective inhibitor of the Janus Associated Kinases JAK1 and JAK2. These specific enzymes mediate the signaling of several cytokines and growth factors that are vital for hematopoiesis and immune function.
- JAK-STAT Pathway Downregulation: By blocking JAK1 and JAK2, the drug interrupts the dysregulated JAK-STAT signaling pathway, which is frequently mutated or overactive in myeloproliferative disorders (such as the JAK2V617F mutation).
- Reduction of Proliferation and Cytokines: This action directly suppresses the abnormal, autonomous proliferation of blood cells, reduces the systemic release of inflammatory cytokines, and decreases bone marrow fibrosis.
- Immune System Modulation: In cases of graft-versus-host disease, inhibiting this pathway tempers the hyper-inflammatory, donor-derived T-cell response targeting host tissues, thereby minimizing systemic tissue damage.
Key Benefits
- Effectively reduces significant splenomegaly (enlarged spleen), providing noticeable physical relief and reducing abdominal discomfort for myelofibrosis patients.
- Alleviates debilitating disease-related systemic symptoms, such as severe fatigue, night sweats, bone pain, fever, and unmanageable pruritus (itching).
- Offers a vital, targeted therapeutic alternative for polycythemia vera patients who can no longer tolerate or fail to respond to standard hydroxyurea therapy.
- Provides a proven clinical intervention to control complex, multi-system inflammation associated with steroid-refractory acute and chronic graft-versus-host disease.
Usage
This highly targeted antineoplastic therapy must be managed strictly by a physician experienced in the administration of hematology and oncology medications. Because this medication can profoundly suppress bone marrow activity, a complete blood count (CBC) must be performed before starting therapy and monitored closely every one to two weeks during the initial weeks of treatment. Dose adjustments, temporary interruptions, or permanent discontinuation are often required based on circulating platelet and absolute neutrophil counts.
| Parameter | Clinical Guidelines |
| Administration Route | For oral use only. Tablets should be swallowed whole with or without food. If a dose is missed, the patient should skip that dose and take the next scheduled dose at the normal time; do not double the dose. |
| Tapering and Withdrawal | Never stop treatment abruptly. Abrupt discontinuation can cause a severe re-emergence of myelofibrosis symptoms, massive spleen enlargement, or life-threatening systemic cytokine rebound shock. |
| Metabolic Interactions | Co-administration with strong CYP3A4 inhibitors (like ketoconazole or clarithromycin) requires a substantial dose reduction, as these substances significantly elevate circulating ruxolitinib levels. |
Uses
Treatment of Primary and Secondary Myelofibrosis: Indicated for the management of patients with intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis to reduce significant spleen volume and control debilitating constitutional symptoms.
Management of Advanced Polycythemia Vera: Prescribed to control systemic symptoms, normalize hematocrit levels, and manage splenomegaly in adult patients who have demonstrated an inadequate response to or a severe intolerance of hydroxyurea.
Therapy for Acute Graft-Versus-Host Disease (aGvHD): Utilized in adult and pediatric patients for the treatment of steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Control of Chronic Graft-Versus-Host Disease (cGvHD): Employed to manage complex, multi-organ inflammation and tissue fibrosis in patients who have failed to respond adequately to initial corticosteroid or systemic immunosuppressive therapies.
Side Effects
Possible Side Effects of Jakavi Tablet (Ruxolitinib)
Jakavi Tablet is a targeted therapy used for blood and bone marrow disorders. It can affect blood counts and the immune system, leading to side effects that require regular monitoring.
| Side Effect Type | Details |
|---|---|
| Common Effects | Anemia, low platelet count. |
| Infection Risk | Increased susceptibility to infections. |
| General Effects | Headache, dizziness, fatigue. |
| Digestive System | Diarrhea, nausea. |
| Skin Effects | Bruising, rash. |
| Metabolic Effects | Weight gain in some patients. |
Common Side Effects
- Fatigue
- Low red blood cell count (anemia)
- Low platelet count
- Headache
Less Common But Important Effects
- Increased risk of infections
- Easy bruising or bleeding
- Dizziness
- Gastrointestinal upset (nausea, diarrhea)
When to Be Careful
- Fever or signs of infection
- Unusual bruising or bleeding
- Severe fatigue or weakness
- Shortness of breath or persistent dizziness
General Note
- Side effects are closely related to blood count changes
- Regular monitoring helps reduce risks
- Report any infection or bleeding symptoms immediately
FAQs
Q: What is Jakavi Tablet used for?
A: This targeted prescription medication is used to treat adults with myelofibrosis (a rare bone marrow cancer), including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. It is also approved for patients with polycythemia vera who do not respond to or cannot tolerate hydroxyurea, as well as patients with acute or chronic graft-versus-host disease (GvHD).
Q: How does Ruxolitinib work to manage these conditions?
A: It functions as a selective inhibitor of JAK1 and JAK2 (Janus Kinase) enzymes. In these diseases, the JAK-STAT signaling pathway is hyperactive, causing abnormal blood cell growth and intense inflammation. By blocking these enzymes, the drug slows down cell proliferation, shrinks an enlarged spleen (splenomegaly), and lowers the production of inflammatory chemicals.
Q: What blood-related side effects should be monitored during treatment?
A: Because JAK inhibitors affect blood cell production, Jakavi can cause severe myelosuppression. This includes a dangerous drop in platelets (thrombocytopenia), low red blood cells (anemia), and low white blood cells (neutropenia). Patients must undergo regular complete blood counts (CBC) so their healthcare provider can adjust the dose if necessary.
Q: Does taking Jakavi increase the risk of developing serious infections?
A: Yes, suppressing the immune system via JAK inhibition makes patients more susceptible to bacterial, mycobacterial, fungal, and viral infections. Serious conditions like tuberculosis, severe sepsis, and shingles (herpes zoster) reactivation can occur.
Q: Can Jakavi treatment be stopped suddenly if side effects occur?
A: No, treatment must never be discontinued abruptly. Stopping the medication suddenly can cause withdrawal-like symptoms, leading to a rapid return of myelofibrosis symptoms, severe inflammation, spleen enlargement, and occasionally life-threatening shock.
Q: Are there any specific dietary or fluid restrictions with this medication?
A: The tablets can be taken with or without food. However, patients should avoid eating grapefruit or drinking grapefruit juice, as compounds in grapefruit can interfere with the liver enzymes (specifically CYP3A4) that break down ruxolitinib.
Interactions
Drug Interactions of Jakavi Tablet (Ruxolitinib)
Jakavi Tablet may interact with medicines that affect the liver enzymes (CYP3A4), immune system, or blood counts. These interactions can change drug levels or increase side effects.
| Medicine or Product Type | Interaction Details |
|---|---|
| Strong CYP3A4 Inhibitors | May increase Ruxolitinib levels and toxicity risk. |
| Strong CYP3A4 Inducers | May reduce effectiveness of treatment. |
| Antifungal Drugs | Can increase blood levels of Jakavi. |
| Antibiotics (some types) | May alter drug metabolism. |
| Immunosuppressants | Can increase infection risk. |
| Anticoagulants | May increase bleeding risk with low platelets. |
| Vaccines (Live) | Should be avoided due to infection risk. |
Important Interaction Advice
- Inform doctor about all medicines before starting treatment
- Avoid grapefruit and grapefruit juice
- Do not start or stop medicines without specialist guidance
- Monitor for infections or unusual bleeding
General Guidance
- Regular blood monitoring is essential during combination therapy
- Dose adjustments may be required with interacting drugs
- Watch for fever, bruising, or fatigue
- Always follow hematologist instructions strictly
Additional Note
- Jakavi is a specialist medicine with significant interaction potential, so full medication disclosure is critical before use
| Manufacturer | : | Novartis Ltd, India |
| Trade Name | : | Jakafi |
| Generic Search | : | Ruxolitinib |
| Strength | : | 5mg, 10mg, 15mg, 20mg |
Latest Products
